Case 2 Presentation: A 77-Year-Old Man With MIBC
Karim Chamie, MD, presents the case of a 77-year-old patient with T2N0M0 MIBC and the potential treatment regimen he would suggest.
EP: 1.Case 1 Presentation: A 60-Year-Old Woman With Muscle-Invasive Bladder Cancer (MIBC)
EP: 2.Determining Cisplatin Eligibility for Patients with MIBC
EP: 3.Available Adjuvant Therapy Options for Patients with Stage II or III MIBC After Previous Cystectomy
EP: 4.Communication and Follow-Up Strategies After Referring a Patient with MIBC to Medical Oncology
EP: 5.Case 2 Presentation: A 77-Year-Old Man With MIBC
EP: 6.Unmet Needs and Clinical Challenges in the Management of MIBC
EP: 7.Potential Future Approaches to Neoadjuvant and Adjuvant Immunotherapy for MIBC
EP: 8.Clinical Pearls for Community Urologists Treating Patients with MIBC
Cell therapy TARA-002 shows initial promise in NMIBC
April 9th 2024"This encouraging anti-tumor activity coupled with a favorable safety profile and mode of administration that is both convenient and familiar to urologists indicates that, if confirmed in future studies, TARA-002 could potentially play a meaningful role in NMIBC treatment in the future," says Timothy D. Lyon, MD.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
Nadofaragene firadenovec shows durable efficacy in NMIBC
April 8th 2024"In this follow-up analysis of the phase 3 study, we demonstrated a sustained response to Adstiladrin treatment over 3 years, allowing more than half of the patients in the study to remain cystectomy free for at least 36 months,” says Colin P.N. Dinney, MD.
